ACIU AC Immune SA

Nasdaq acimmune.com


$ 2.77 $ -0.12 (-4.3 %)    

Wednesday, 22-Oct-2025 18:26:15 EDT
QQQ $ 605.44 $ -5.89 (-0.96 %)
DIA $ 465.24 $ -3.44 (-0.73 %)
SPY $ 667.70 $ -3.49 (-0.52 %)
TLT $ 92.20 $ 0.06 (0.07 %)
GLD $ 376.41 $ 0.04 (0.01 %)
$ 2.67
$ 2.78
$ 2.75 x 100
$ 2.79 x 20
$ 2.63 - $ 2.84
$ 1.43 - $ 3.99
275,845
na
268.1M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 btig-reiterates-buy-on-ac-immune-maintains-8-price-target

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

 ac-immune-q2-eps-021-misses-017-estimate-sales-154m-miss-198m-estimate

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) b...

Core News & Articles

https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%...

 hc-wainwright--co-maintains-buy-on-ac-immune-lowers-price-target-to-12

HC Wainwright & Co. analyst Andrew Fein maintains AC Immune (NASDAQ:ACIU) with a Buy and lowers the price target from $1...

 ac-immune-q1-eps-021-misses-020-estimate-sales-110m-beat-30067k-estimate

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) b...

 hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

 ac-immune-reports-further-interim-results-from-phase-2-trial-of-aci-7104056-active-immunotherapy-in-early-parkinsons-disease-says-repeated-immunizations-amplify-the-anti-a-syn-antibody-response

Interim results show positive antibody responses were effectively induced against the target antigen at week 6 after 2 immuniza...

 hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

 ac-immune-aci-24060-was-generally-safe-and-well-tolerated-in-individuals-with-down-syndrome-with-no-serious-adverse-events-related-to-the-study-drug

No cases of amyloid-related imaging abnormalities observed in this study population. Based upon these findings, AC Immune plans...

 hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

 ac-immunes-active-immunotherapy-shows-antibody-responses-in-early-parkinsons-patients

AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.

 hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION